



HAL
open science

Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study

Simone Tunesi, Damien Le Dû, Gina Gualano, Joan-Pau Millet, Aliaksandr Skrahin, Graham Bothamley, Xavier Casas, Delia Goletti, Christoph Lange, Maria Musso, et al.

► To cite this version:

Simone Tunesi, Damien Le Dû, Gina Gualano, Joan-Pau Millet, Aliaksandr Skrahin, et al.. Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study. *Journal of Infection*, In press, 84 (6), pp.834–872. 10.1016/j.jinf.2022.03.004 . hal-03608140

HAL Id: hal-03608140

<https://hal.sorbonne-universite.fr/hal-03608140v1>

Submitted on 16 Feb 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and**
2 **ESGMYC study**

3

4 **Word count:** 992

5 **Figure:** 1 **Tables:** 1 **References:** 10

6

7 **Authors:**

8 Simone Tunesi,¹ Damien Le Dû,² Gina Gualano,^{3#} Joan-Pau Millet,^{4#} Aliaksandr Skrahin,^{5#} Graham
9 Bothamley,⁶ Xavier Casas,⁷ Delia Goletti,³ Christoph Lange,⁸ Maria Musso,³ Fabrizio Palmieri,³ Valérie
10 Pourcher,⁹ Christophe Rioux,¹⁰ Alena Skrahina,⁵ Nicolas Veziris,¹¹⁻¹³ Dzmitry Viatushka,⁵ Mathilde
11 Jachym-Fréchet,² Lorenzo Guglielmetti^{12,13} for the TBnet,* the ESGMYC,** and the French MDR-TB
12 Group***

13

14 #The authors contributed equally to this study.

15 *Tuberculosis Network European Trialsgroup

16 **ESCMID (European Society on Clinical Microbiology and Infectious Diseases) Study Group on
17 Mycobacterial Infections

18 ***Members of the French MDR-TB Group are the following: Dhiba Marigot-Outtandy (Bligny),
19 Xavier Lescure, Marie Dubert, and Yazdan Yazdanpanah (Paris-Bichat), Eric Caumes, Pascaline
20 Choinier and Elie Haddad (Paris-Pitié-Salpêtrière), Jakub Kowalczyk (Mulhouse), Hélène Laurichesse
21 and Olivier Lesens (Clermont Ferrand), Alexandra Aubry, Isabelle Bonnet, and Florence Morel (Paris-
22 CNR Mycobactéries).

23

24 **Affiliations:**

- 25 1. Infectious Diseases Unit, ASST Valle Olona, Busto Arsizio, Italy.
26 2. Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France.

- 27 3. National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy
- 28 4. Serveis Clínics, Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP),
29 Barcelona, Spain.
- 30 5. The Republican Research and Practical Center for Pulmonology and TB, Minsk, Belarus.
- 31 6. Homerton University Hospital, London E9 6SR, UK; Queen Mary University of London, UK;
32 London School of Hygiene and Tropical Medicine, UK.
- 33 7. Serveis Clinics, Barcelona, Spain.
- 34 8. Research Center Borstel, Clinical Infectious Diseases, Borstel, Germany; German Center for
35 Infection Research (DZIF) Tuberculosis Unit, Borstel, Germany; Respiratory Medicine &
36 International Health, University of Lübeck, Lübeck, Germany; Global TB Program, Baylor
37 College of Medicine and Texas Children's Hospital, Houston, TX, USA.
- 38 9. APHP, Service des Maladies Infectieuses et Tropicales, Sorbonne Université, Site Pitié, Paris,
39 France; Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Inserm UMR_S
40 1136, Paris, France.
- 41 10. APHP, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris,
42 France.
- 43 11. APHP, Groupe Hospitalier Universitaire Sorbonne Université, site Saint-Antoine,
44 Département de bactériologie, Paris, France.
- 45 12. APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière,
46 Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux
47 Antituberculeux, Paris, France.
- 48 13. Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses,
49 Cimi-Paris, équipe 13, Paris, France.

50

51 **Corresponding author:**

52 Lorenzo Guglielmetti

53 Laboratoire de Bactériologie-Hygiène, Faculté de Médecine Sorbonne Université, 91 Boulevard de
54 l'hôpital, 75634 Paris Cedex 13, France; e-mail: lorenzo.guglielmetti@aphp.fr; tel: +33 1 40 77 97 56

55

56 **Author contributions:**

57 LG and ST made a substantial contribution to the conception and design of the work, to the
58 acquisition, analysis and interpretation of data for the work, performed statistical analysis, wrote the
59 manuscript, critically revised the manuscript for important intellectual content, gave final approval
60 of the current version to be published, and agree to be accountable for all aspects of the work in
61 ensuring that questions related to the accuracy or integrity of any part of the work are appropriately
62 investigated and resolved.

63 DLD and MJF made a substantial contribution to the conception and design of the work, to the
64 acquisition and interpretation of data for the work, critically revised the manuscript for important
65 intellectual content, gave final approval of the current version to be published, and agree to be
66 accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity
67 of any part of the work are appropriately investigated and resolved.

68 GG, JPM, and AS made a contribution to the conception and design of the work, to the acquisition
69 and interpretation of data for the work, critically revised the manuscript for important intellectual
70 content, gave final approval of the current version to be published, and agree to be accountable for
71 all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of
72 the work are appropriately investigated and resolved.

73 All other authors made a substantial contribution to the conception and design of the work, to the
74 acquisition and interpretation of data for the work, critically revised the manuscript for important
75 intellectual content, gave final approval of the current version to be published, and agree to be
76 accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity
77 of any part of the work are appropriately investigated and resolved.

78

79 **Financial and competing interest disclosure:**

80 No funding to declare for the present work.

81

82 **RUNNING TITLE:**

83 Co-treatment of HCV and MDR-TB is safe and effective